Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia by Mohamed Bradai, Mohand Tayeb Abad, Serge Pissard, Fatima Lamraoui,

Slides:

Advertisements

Similar presentations

RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3): August 1, 2005 ©2005 by American Society.

Advertisements

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.

Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry by Po-Lin Chiu, George M. Bou-Assaf,

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson,

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

The influence of high-altitude living on body iron

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Do HSCs divide asymmetrically?

Hydroxyurea makes inflammation “just right”?

TCR-MHC-peptide(s): in vivo veritas

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

by Khaled M. Musallam, Vijay G

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma by Jean-Louis H. Kerkhoffs,

Defects in DBA: more than meets the eye

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,

Next-generation leukemia immunotherapy

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Tax fingerprint in adult T-cell leukemia

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Nonmyeloablative conditioning for relapsed follicular lymphoma

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

Genetic sequence analysis of inherited bleeding diseases

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Hemoglobin levels in African-Americans

Acute promyelocytic leukemia, microgranular variant

Erythropoietin Receptor Mutations Associated With Familial Erythrocytosis Cause Hypersensitivity to Erythropoietin in the Heterozygous State by Stephanie.

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent by Sylvia T. Singer, Vivian.

by Alexander Röth, Andreas Hüttmann, Russell P

An actuarial GPS for hemophilic longevity

New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years by Pietro Sodani, David Gaziev, Paola Polchi,

Successful Treatment of Iron Overload by Phlebotomies in a Patient With Severe Congenital Dyserythropoietic Anemia Type II by W.K. Hofmann, J.P. Kaltwasser,

by Sabah Sallah, and Jim Y. Wan

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Has MRD monitoring superseded other prognostic factors in adult ALL?

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

HU for acute treatment of sickle VOC?

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Anergy: the CLL cell limbo

by John J. Strouse, Megan E. Reller, David G

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Chapter 4: Red cell transfusion to treat anemia in CKD

Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea by Françoise Bernaudin, Cécile Arnaud,

by Geling Li, Emily Waite, and Julie Wolfson

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

by Michael R. DeBaun, and Ellen Wright Clayton

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

by Wendy Lim, Sara K. Vesely, and James N. George

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Assessment of Hematological Data in a Cohort of European Children with Sickle Cell Anemia Treated with Hydroxyurea: Can European Centers Apply Today the.

Rituximab immunotherapy: it’s getting personal

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

A binding relationship with thrombin

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Initial treatment of CLL: integrating biology and functional status

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Cold agglutinin disease

Presentation transcript:

Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia by Mohamed Bradai, Mohand Tayeb Abad, Serge Pissard, Fatima Lamraoui, Laurent Skopinski, and Mariane de Montalembert Blood Volume 102(4):1529-1530 August 15, 2003 ©2003 by American Society of Hematology

Hb levels under HU. Changes in hemoglobin (Hb) levels with hydroxyurea treatment in 7 transfusion-dependent β-thalassemic children. Hb levels under HU. Changes in hemoglobin (Hb) levels with hydroxyurea treatment in 7 transfusion-dependent β-thalassemic children. Mohamed Bradai et al. Blood 2003;102:1529-1530 ©2003 by American Society of Hematology